Betting on Tech
Health Care: Drugs
Aegerion Pharmaceuticals Inc. (AEGR: NASDAQ)
$63.70 1.36 | 2.18%
06/18/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Sales | 0.00 | 0.00 | 0.00 | -28.39K |
| Gross Operating Profit | 0.00 | 0.00 | 0.00 | 28.39K |
| Selling, General, and Administrative Expenses | 34.08M | 14.71M | 5.92M | 3.07M |
| Research & Development | 25.16M | 23.69M | 7.63M | 7.04M |
| Operating Income before D & A (EBITDA) | -59.24M | -38.40M | -13.55M | -10.09M |
| Depreciation & Amortization | 1.23M | 407.26K | 9.98K | 28.39K |
| Interest Income | 162.00K | 209.28K | 109.06K | 177.16K |
| Other Income - Net | -883.00K | 747.78K | -201.79K | -174.42K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -62.56M | -38.76M | -13.65M | -10.11M |
| Interest Expense | 937.00K | 1.11M | 2.40M | 2.08M |
| Pre-Tax Income | -63.49M | -39.88M | -16.06M | -12.20M |
| Income Taxes | 0.00 | 0.00 | -1.79M | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -62.26M | -39.47M | -14.25M | -12.20M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -62.26M | -39.47M | -14.25M | -12.20M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -62.26M | -39.47M | -14.25M | -12.20M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-60.90M | -38.56M | -14.25M | -12.20M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -62.26M | -39.47M | -23.00M | -15.48M |
| Basic EPS from Continuing Ops. | -2.64 | -2.03 | -5.07 | -3.20 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -2.64 | -2.03 | -5.07 | -3.20 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -2.64 | -2.03 | -5.07 | -3.20 |
| Basic Normalized Net Income/Share | -2.58 | -1.98 | -5.07 | -3.20 |
| EPS fr Continuing Ops. | -2.64 | -2.03 | -5.07 | -3.20 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -2.64 | -2.03 | -5.07 | -3.20 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -2.64 | -2.03 | -5.07 | -3.20 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-2.58 | -1.98 | -5.07 | -3.20 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with AEGR
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- ContributorDrugs Facing FDA Approval i...
- ContributorStocks Rising On Unusal Vol...
- ContributorStocks With Big Insider Buy...
Latest AEGR Headlines from TheStreet
- Aegerion Pharmaceuticals To Announce First Quarter 2013 Financial Results On Tuesday, April 30 04.16.13 | 08:04 am
- Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program 04.03.13 | 04:04 pm
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- 10 Stocks Insiders And Hedge Funds Think Will Go Higher 03.11.13 | 01:03 pm
- Aegerion Pharmaceuticals Announces Fourth-Quarter And Year-End 2012 Financial Results 03.06.13 | 07:03 am
- Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program 03.05.13 | 04:03 pm
- 5 Stocks Set to Soar on Bullish Earnings 03.04.13 | 01:03 pm
- Aegerion Pharmaceuticals Observes Rare Disease Day 02.28.13 | 08:02 am
- Aegerion Pharmaceuticals Announces Presentation At The Cowen And Company 33rd Annual Health Care Conference 02.27.13 | 08:02 am
- Aegerion Pharmaceuticals To Announce Fourth Quarter 2012 Financial Results On Wednesday, March 6 02.20.13 | 08:02 am
Press Releases for AEGR
- Insmed Appoints Will Lewis As President And Chief Executive Officer - PR Newswire 09.11.12 | 08:09 am
- Aegerion Pharmaceuticals Chief Executive Officer Marc D. Beer (Video: Business Wire) - Business Wire 09.29.11 | 08:09 am
Partner Headlines for AEGR
- Insider Buying Trends: Are These Cash Rich Companies Ready To Rally? - Seeking Alpha 03.15.13 | 09:03 am
- UPDATE: Canaccord Genuity Raises PT to $44 on Aegerion Pharmaceuticals on Encouraging Sales Data - Benzinga 03.07.13 | 01:03 pm
- UPDATE: Deutsche Bank Raises PT on Aegerion Pharmaceuticals on Strong Juxtapid Uptake - Benzinga 03.06.13 | 01:03 pm
- Pre-Market Earnings Report for March 6, 2013 : SPLS, BF/B, AEO, TFM, BIG, AEGR, HOV, WD, TRK, QRE, WILN, MFB - NASDAQ 03.05.13 | 09:03 pm
- Calendar Spreads On Intuitive Surgical, Riverbed Technology And Sandisk - Seeking Alpha 10.19.12 | 09:10 am
- Benzinga Mid-Day Market Update - Benzinga 10.17.12 | 12:10 pm
- 5 Pharmaceutical Companies With EMA Catalysts During The Next 3 - 12 Months - Part II - Seeking Alpha 09.02.12 | 08:09 am
- Aegerion Pharmaceuticals Announces Date of FDA Advisory Committee Review of Lomitapide NDA - Benzinga 08.14.12 | 09:08 am
- 16 Healthcare Stocks Deeply Discounted From Target Price - Seeking Alpha 01.12.12 | 09:01 am
- UPDATE: Aegerion Pharmaceuticals Files Registration Statement for Proposed Offering of 4.25M Shares - Benzinga 06.16.11 | 04:06 pm
